Forskellen mellem gennemsnitlig ændring fra baseline til uge 26/ afslutning (LOCF, Last Observation Carried Forward) var statistisk signifikant (UPDRS, del I- III: forskellen mellem rasagilin 1 mg sammenlignet med placebo var ÷4, 2, 95% CI [÷5, 7; ÷2, 7]; p < 0, 0001; forskellen mellem rasagilin 2 mg sammenlignet med placebo var ÷3, 6, 95% CI [÷5, 0; ÷2, 1]; p < 0, 0001, UPDRS Motor, del II: forskellen mellem rasagilin 1 mg sammenlignet med placebo var ÷2, 7; 95% CI [÷3, 87; ÷1, 55], p < 0, 0001; forskellen mellem rasagilin 2 mg sammenlignet med placebo var ÷1, 68; 95% CI [÷2, 85; ÷0, 51], p=0, 0050).
The difference between the mean change from baseline to week 26/ termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI [-5.7, -2.7]; p < 0.0001; for rasagiline 2 mg compared to placebo -3.6, 95% CI [-5.0, -2.1]; p < 0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95% CI [-3.87, -1.55], p < 0.0001; for rasagiline 2 mg compared to placebo -1.68, 95% CI [-2.85, -0.51], p=0.0050).